At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Pembrolizumab 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Hodgkin's Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL). Completed, enrolled 66 participants across 27 sites in 11 countries.
Detailed Summary
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil, Canada, Czechia, France, Italy, Poland, Russia, South Africa, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionDec 2023
Study CompletionOct 2025
TodayJul 2026
First PostedMay 6, 2021
Enrollment StartJun 7, 2021
Primary CompletionDec 14, 2023
Study CompletionOct 13, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.2 years ago
Interventions
Pembrolizumabbiological
Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.